Back to search

Article

A Real-World Cohort Study of First-Line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer in Vietnam

2023-10-12

Abstract excerpt

<h4>Background: </h4> This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam. <h4>Methods: </h4>: This retrospective study was conducted across nine hospitals in Vietnam. Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received afatinib as first-line therapy between April 2018 and June 2...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9650e3a2-eaa7-59e0-b3a7-79560ff480d5
DOI
10.21203/rs.3.rs-3399075/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Real-World Cohort Study of First-Line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer in VietnamDOI 10.21203/rs.3.rs-3399075/v1
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.Semantic proximity
Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.Semantic proximity
Efficacy and Tolerance of First-Line Afatinib in Elderly NSCLC Patients with EGFR Mutations in Vietnam: A Multicenter Real-World Study.Semantic proximity
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.Semantic proximity
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.Semantic proximity
Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.Semantic proximity
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.Semantic proximity
Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.Semantic proximity
An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib.Semantic proximity
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity
Treatment Patterns and Survival Outcomes in a Real-World Cohort of 263 Patients with EGFR L858R-Mutant Non-Small Cell Lung Cancer: Focus on EGFR-TKI Selection.Semantic proximity
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.Semantic proximity
Select a neighboring publication to make it the new centre.